Mutant oncogenes: targets for therapy
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
London u.a.
Chapman & Hall Med.
1993
|
| Ausgabe: | 1. ed. |
| Schlagworte: | |
| Beschreibung: | X, 209 S. Ill., graph. Darst. |
| ISBN: | 0412481103 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV008058830 | ||
| 003 | DE-604 | ||
| 005 | 19930803 | ||
| 007 | t | ||
| 008 | 930722s1993 ad|| |||| 00||| engod | ||
| 020 | |a 0412481103 |9 0-412-48110-3 | ||
| 035 | |a (OCoLC)26895325 | ||
| 035 | |a (DE-599)BVBBV008058830 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-12 |a DE-29 | ||
| 050 | 0 | |a RC268.42 | |
| 082 | 0 | |a 616.99/4042 |2 20 | |
| 084 | |a XH 3200 |0 (DE-625)152888:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Mutant oncogenes |b targets for therapy |c ed. by Nicholas R. Lemoine ... |
| 250 | |a 1. ed. | ||
| 264 | 1 | |a London u.a. |b Chapman & Hall Med. |c 1993 | |
| 300 | |a X, 209 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 2 | |a Gènes suppresseurs de tumeur - Congrès comme sujet | |
| 650 | 7 | |a Kanker |2 gtt | |
| 650 | 7 | |a Kankerverwekkende stoffen |2 gtt | |
| 650 | 2 | |a Oncogènes - Génétique - Congrès comme sujet | |
| 650 | 2 | |a Protéines oncogènes - usage thérapeutique - Congrès comme sujet | |
| 650 | 7 | |a Therapieën |2 gtt | |
| 650 | 2 | |a Tumeurs - Thérapeutique - Congrès comme sujet | |
| 650 | 4 | |a Cancer |x Gene therapy | |
| 650 | 4 | |a Cancer |x Immunotherapy | |
| 650 | 4 | |a Cancer |x Molecular aspects | |
| 650 | 4 | |a Genes, Tumor Suppressor |v Congresses | |
| 650 | 4 | |a Neoplasms |x therapy |v Congresses | |
| 650 | 4 | |a Oncogene Proteins |x therapeutic use |v Congresses | |
| 650 | 4 | |a Oncogenes | |
| 650 | 4 | |a Oncogenes |x genetics |v Congresses | |
| 650 | 0 | 7 | |a Suppressorgen |0 (DE-588)4278851-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Onkogen |0 (DE-588)4131118-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Monoklonaler Antikörper |0 (DE-588)4040094-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Mutante |0 (DE-588)4256709-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakologischer Antagonist |0 (DE-588)4198682-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Immuntherapie |0 (DE-588)4026640-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Wachstumsfaktor |0 (DE-588)4188802-9 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1991 |z London |2 gnd-content | |
| 689 | 0 | 0 | |a Onkogen |0 (DE-588)4131118-8 |D s |
| 689 | 0 | 1 | |a Mutante |0 (DE-588)4256709-9 |D s |
| 689 | 0 | 2 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 3 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | 1 | |a Wachstumsfaktor |0 (DE-588)4188802-9 |D s |
| 689 | 1 | 2 | |a Pharmakologischer Antagonist |0 (DE-588)4198682-9 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 2 | 1 | |a Suppressorgen |0 (DE-588)4278851-1 |D s |
| 689 | 2 | |5 DE-604 | |
| 689 | 3 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 3 | 1 | |a Onkogen |0 (DE-588)4131118-8 |D s |
| 689 | 3 | 2 | |a Monoklonaler Antikörper |0 (DE-588)4040094-3 |D s |
| 689 | 3 | 3 | |a Immuntherapie |0 (DE-588)4026640-0 |D s |
| 689 | 3 | |5 DE-604 | |
| 700 | 1 | |a Lemoine, Nicholas R. |e Sonstige |4 oth | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-005303164 | ||
Datensatz im Suchindex
| _version_ | 1804122424479842304 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV008058830 |
| callnumber-first | R - Medicine |
| callnumber-label | RC268 |
| callnumber-raw | RC268.42 |
| callnumber-search | RC268.42 |
| callnumber-sort | RC 3268.42 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | XH 3200 |
| ctrlnum | (OCoLC)26895325 (DE-599)BVBBV008058830 |
| dewey-full | 616.99/4042 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4042 |
| dewey-search | 616.99/4042 |
| dewey-sort | 3616.99 44042 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 1. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03073nam a2200805 c 4500</leader><controlfield tag="001">BV008058830</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19930803 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">930722s1993 ad|| |||| 00||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0412481103</subfield><subfield code="9">0-412-48110-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)26895325</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV008058830</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-29</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC268.42</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/4042</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3200</subfield><subfield code="0">(DE-625)152888:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Mutant oncogenes</subfield><subfield code="b">targets for therapy</subfield><subfield code="c">ed. by Nicholas R. Lemoine ...</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London u.a.</subfield><subfield code="b">Chapman & Hall Med.</subfield><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">X, 209 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Gènes suppresseurs de tumeur - Congrès comme sujet</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Kanker</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Kankerverwekkende stoffen</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Oncogènes - Génétique - Congrès comme sujet</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Protéines oncogènes - usage thérapeutique - Congrès comme sujet</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapieën</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Tumeurs - Thérapeutique - Congrès comme sujet</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Gene therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Molecular aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Genes, Tumor Suppressor</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">therapy</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncogene Proteins</subfield><subfield code="x">therapeutic use</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncogenes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncogenes</subfield><subfield code="x">genetics</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Suppressorgen</subfield><subfield code="0">(DE-588)4278851-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Onkogen</subfield><subfield code="0">(DE-588)4131118-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Monoklonaler Antikörper</subfield><subfield code="0">(DE-588)4040094-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Mutante</subfield><subfield code="0">(DE-588)4256709-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakologischer Antagonist</subfield><subfield code="0">(DE-588)4198682-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Wachstumsfaktor</subfield><subfield code="0">(DE-588)4188802-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1991</subfield><subfield code="z">London</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Onkogen</subfield><subfield code="0">(DE-588)4131118-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Mutante</subfield><subfield code="0">(DE-588)4256709-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Wachstumsfaktor</subfield><subfield code="0">(DE-588)4188802-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Pharmakologischer Antagonist</subfield><subfield code="0">(DE-588)4198682-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Suppressorgen</subfield><subfield code="0">(DE-588)4278851-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="3" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="1"><subfield code="a">Onkogen</subfield><subfield code="0">(DE-588)4131118-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="2"><subfield code="a">Monoklonaler Antikörper</subfield><subfield code="0">(DE-588)4040094-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="3"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lemoine, Nicholas R.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-005303164</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 1991 London gnd-content |
| genre_facet | Konferenzschrift 1991 London |
| id | DE-604.BV008058830 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T17:13:39Z |
| institution | BVB |
| isbn | 0412481103 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-005303164 |
| oclc_num | 26895325 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-12 DE-29 |
| owner_facet | DE-355 DE-BY-UBR DE-12 DE-29 |
| physical | X, 209 S. Ill., graph. Darst. |
| publishDate | 1993 |
| publishDateSearch | 1993 |
| publishDateSort | 1993 |
| publisher | Chapman & Hall Med. |
| record_format | marc |
| spelling | Mutant oncogenes targets for therapy ed. by Nicholas R. Lemoine ... 1. ed. London u.a. Chapman & Hall Med. 1993 X, 209 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Gènes suppresseurs de tumeur - Congrès comme sujet Kanker gtt Kankerverwekkende stoffen gtt Oncogènes - Génétique - Congrès comme sujet Protéines oncogènes - usage thérapeutique - Congrès comme sujet Therapieën gtt Tumeurs - Thérapeutique - Congrès comme sujet Cancer Gene therapy Cancer Immunotherapy Cancer Molecular aspects Genes, Tumor Suppressor Congresses Neoplasms therapy Congresses Oncogene Proteins therapeutic use Congresses Oncogenes Oncogenes genetics Congresses Suppressorgen (DE-588)4278851-1 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf Onkogen (DE-588)4131118-8 gnd rswk-swf Monoklonaler Antikörper (DE-588)4040094-3 gnd rswk-swf Mutante (DE-588)4256709-9 gnd rswk-swf Pharmakologischer Antagonist (DE-588)4198682-9 gnd rswk-swf Immuntherapie (DE-588)4026640-0 gnd rswk-swf Wachstumsfaktor (DE-588)4188802-9 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 1991 London gnd-content Onkogen (DE-588)4131118-8 s Mutante (DE-588)4256709-9 s Krebs Medizin (DE-588)4073781-0 s Therapie (DE-588)4059798-2 s DE-604 Wachstumsfaktor (DE-588)4188802-9 s Pharmakologischer Antagonist (DE-588)4198682-9 s Suppressorgen (DE-588)4278851-1 s Monoklonaler Antikörper (DE-588)4040094-3 s Immuntherapie (DE-588)4026640-0 s Lemoine, Nicholas R. Sonstige oth |
| spellingShingle | Mutant oncogenes targets for therapy Gènes suppresseurs de tumeur - Congrès comme sujet Kanker gtt Kankerverwekkende stoffen gtt Oncogènes - Génétique - Congrès comme sujet Protéines oncogènes - usage thérapeutique - Congrès comme sujet Therapieën gtt Tumeurs - Thérapeutique - Congrès comme sujet Cancer Gene therapy Cancer Immunotherapy Cancer Molecular aspects Genes, Tumor Suppressor Congresses Neoplasms therapy Congresses Oncogene Proteins therapeutic use Congresses Oncogenes Oncogenes genetics Congresses Suppressorgen (DE-588)4278851-1 gnd Krebs Medizin (DE-588)4073781-0 gnd Therapie (DE-588)4059798-2 gnd Onkogen (DE-588)4131118-8 gnd Monoklonaler Antikörper (DE-588)4040094-3 gnd Mutante (DE-588)4256709-9 gnd Pharmakologischer Antagonist (DE-588)4198682-9 gnd Immuntherapie (DE-588)4026640-0 gnd Wachstumsfaktor (DE-588)4188802-9 gnd |
| subject_GND | (DE-588)4278851-1 (DE-588)4073781-0 (DE-588)4059798-2 (DE-588)4131118-8 (DE-588)4040094-3 (DE-588)4256709-9 (DE-588)4198682-9 (DE-588)4026640-0 (DE-588)4188802-9 (DE-588)1071861417 |
| title | Mutant oncogenes targets for therapy |
| title_auth | Mutant oncogenes targets for therapy |
| title_exact_search | Mutant oncogenes targets for therapy |
| title_full | Mutant oncogenes targets for therapy ed. by Nicholas R. Lemoine ... |
| title_fullStr | Mutant oncogenes targets for therapy ed. by Nicholas R. Lemoine ... |
| title_full_unstemmed | Mutant oncogenes targets for therapy ed. by Nicholas R. Lemoine ... |
| title_short | Mutant oncogenes |
| title_sort | mutant oncogenes targets for therapy |
| title_sub | targets for therapy |
| topic | Gènes suppresseurs de tumeur - Congrès comme sujet Kanker gtt Kankerverwekkende stoffen gtt Oncogènes - Génétique - Congrès comme sujet Protéines oncogènes - usage thérapeutique - Congrès comme sujet Therapieën gtt Tumeurs - Thérapeutique - Congrès comme sujet Cancer Gene therapy Cancer Immunotherapy Cancer Molecular aspects Genes, Tumor Suppressor Congresses Neoplasms therapy Congresses Oncogene Proteins therapeutic use Congresses Oncogenes Oncogenes genetics Congresses Suppressorgen (DE-588)4278851-1 gnd Krebs Medizin (DE-588)4073781-0 gnd Therapie (DE-588)4059798-2 gnd Onkogen (DE-588)4131118-8 gnd Monoklonaler Antikörper (DE-588)4040094-3 gnd Mutante (DE-588)4256709-9 gnd Pharmakologischer Antagonist (DE-588)4198682-9 gnd Immuntherapie (DE-588)4026640-0 gnd Wachstumsfaktor (DE-588)4188802-9 gnd |
| topic_facet | Gènes suppresseurs de tumeur - Congrès comme sujet Kanker Kankerverwekkende stoffen Oncogènes - Génétique - Congrès comme sujet Protéines oncogènes - usage thérapeutique - Congrès comme sujet Therapieën Tumeurs - Thérapeutique - Congrès comme sujet Cancer Gene therapy Cancer Immunotherapy Cancer Molecular aspects Genes, Tumor Suppressor Congresses Neoplasms therapy Congresses Oncogene Proteins therapeutic use Congresses Oncogenes Oncogenes genetics Congresses Suppressorgen Krebs Medizin Therapie Onkogen Monoklonaler Antikörper Mutante Pharmakologischer Antagonist Immuntherapie Wachstumsfaktor Konferenzschrift 1991 London |
| work_keys_str_mv | AT lemoinenicholasr mutantoncogenestargetsfortherapy |